This upward trend is likely influenced by the persistently high rates of untreated T2DM, despite significant advancements in diabetes treatment, particularly the introduction of glucagon-like peptide-1 (GLP-1) receptor agonists (Fig. 4) [8, 10]. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.